Progyny Stock Price and Value Analysis

Progyny (NASDAQ:PGNY) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold Progyny to reach your target.

Target type

PGNY Free Cash Flow Trend

Free Cash Flow trendline for PGNY
Free Cash Flow trendline for Progyny
CSV

Based on historical returns, we believe that Progyny can grow its free cash at a rate of about 17%. That's positive!

AdvantagesDisadvantagesNeutral
  • This company is making money at a great rate!
  • This company has wild ups and downs.
  • This company is less known than others.
  • This stock looks overpriced.
  • This company pays no dividend.

Inside the PGNY Numbers

PGNY Price
(Progyny stock price per share)
$35.71
[?] PGNY Fair Price
(based on intrinsic value)
$7.01
[?] PGNY Safety Price (based on a variable margin of safety) $4.21
Try your own return

The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value.

Value per share:

[?] PE Ratio versus Sector 60% higher than other Healthcare stocks
[?] PE Ratio versus Industry 0% lower than other Medical Care Facilities stocks
[?] Free Cash Flow Jitter 39%

Insider Activity Summary

No open-market insider buys or sells are recorded for the last 12 months.

Recent Insider Activity

Open-market buys and sells reported by Progyny's officers, directors, and 10% owners on SEC Form 4. Routine transactions (tax withholding, option exercises, and stock grants) are excluded -- these are discretionary trades only.

Date Insider Type Shares Price
2021-07-02 TPG Group Holdings (SBS) Advisors, Inc. Sell 33,803 $60.14
2021-07-01 TPG Group Holdings (SBS) Advisors, Inc. Sell 168,929 $60.42
2020-12-17 TPG Group Holdings (SBS) Advisors, Inc. Sell 31,063 $40.07
2020-12-17 TPG Group Holdings (SBS) Advisors, Inc. Sell 26,684 $39.62
2020-12-16 TPG Group Holdings (SBS) Advisors, Inc. Sell 45,974 $40.34
2020-12-16 TPG Group Holdings (SBS) Advisors, Inc. Sell 43,676 $41.10
2020-12-10 TPG Group Holdings (SBS) Advisors, Inc. Sell 67,908 $37.57
2020-12-10 TPG Group Holdings (SBS) Advisors, Inc. Sell 5,192 $36.93
2020-12-09 TPG Group Holdings (SBS) Advisors, Inc. Sell 34,483 $37.74
2020-12-09 TPG Group Holdings (SBS) Advisors, Inc. Sell 50,628 $36.88

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 4,758,154 shares shorted. With 67,175,943 shares available for purchase and an average trading volume over the past 10 trading days of 1,101,870, it would take at least 4.3 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Each year names the SEC filer that reported it, so a change of filer shows up here.

Fiscal yearSEC filer (CIK)Free cash flow (USD millions)
2017 1551306 -10.1
2018 1551306 1.7
2019 1551306 -2.9
2020 1551306 34.9
2021 1551306 24.6
2022 1551306 78.4
2023 1551306 186
2024 1551306 176
2025 1551306 204

Download the yearly data as CSV.

Cash Conversion

How to read this: what free cash flow is, why earnings matter.

Over the 7 fiscal years from 2017 to 2025 with positive net income, operating cash flow totaled $723 million against net income of $318 million, or 2.27 times. Net income was negative in 2 of the 9 years, and those years are left out of the ratio.

In 2025, capital expenditures were $18.4 million, 8.8% of operating cash flow of $210 million, which leaves an estimated $192 million after capex. Across the 7 years with reported capex, it averaged 4.8% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2017 -12.5 -9.5 0.6 n/a
2018 0.7 2.3 0.6 3.44
2019 -8.6 -1.5 3 n/a
2020 46.5 36.2 1 0.78
2021 65.8 26 2.1 0.40
2022 30.4 80.4 3.2 2.65
2023 62 189 3.6 3.04
2024 54.3 179 5.4 3.30
2025 58.5 210 18.4 3.59

Where the Cash Went

How to read this: why companies buy back shares, dividend yield explained.

Over the 4 fiscal years from 2018 to 2025 with dividend or share repurchase facts, estimated free cash flow totaled $378 million. That estimate uses the average of up to five years of capital expenditures, not each year's own, so it is not a reported figure.

In 3 of the 4 years, cash spent repurchasing shares was at least 5% of that year's estimated free cash flow, and in those years it totaled $383 million. Smaller amounts are left out of this sentence because they can be shares withheld to pay employees' taxes on stock awards.

In 2025, cash spent repurchasing shares was $81.7 million, 40.1% of estimated free cash flow of $204 million.

Fiscal yearEstimated free cash flow (USD millions)Dividends paid (USD millions)Cash spent repurchasing shares (USD millions)Total returned (USD millions)Total as a percent of estimated free cash flow
2018 1.7 n/a 1.2 1.2 71.9%
2019 -2.9 n/a 0.2 0.2 n/a
2024 176 n/a 300 300 170.6%
2025 204 n/a 81.7 81.7 40.1%

Free cash flow here is an estimate: operating cash flow less the average of up to five years of capital expenditures. Cash spent repurchasing shares can include shares withheld to pay employees' taxes on stock awards. The entry n/a means the filings gave no usable figure, not that the amount was zero. Source: the company's annual reports to the SEC.

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $48.6 million in 2017 and $1,289 million in 2025, a compound annual growth rate of 50.6% over 8 years. The starting revenue was under 10% of the latest, so that rate comes from a small base and says little about recent growth.

Revenue rose 10.4% from 2024 to 2025.

Our estimated free cash flow was $204 million in 2025, 15.8% of revenue. In 2017 the estimated margin was negative 20.8%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2017 48.6 -10.1 -20.8%
2018 105 1.7 1.6%
2019 230 -2.9 -1.3%
2020 345 34.9 10.1%
2021 501 24.6 4.9%
2022 787 78.4 10.0%
2023 1,089 186 17.1%
2024 1,167 176 15.1%
2025 1,289 204 15.8%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2025, cash and equivalents were $112 million against total liabilities of $226 million, or 49.6% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 30.5% of total assets in 2025, compared with 330.2% in 2018, a decrease of 299.7 percentage points.

Stockholders equity was $516 million in 2025, up from negative equity of -$95.1 million in 2018.

Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 47.6% in 2025. Invested capital here is total assets less cash and current liabilities.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2018 41.3 0.1 136 -95.1
2019 150 80.4 36.2 114
2020 254 70.3 87 167
2021 358 91.4 106 252
2022 543 120 166 377
2023 757 97.3 203 553
2024 607 162 185 422
2025 742 112 226 516

Price Versus Our Estimated Value

Our fair value estimate for Progyny is $7.01, below its current price of $35.71.

Free cash flow was positive in 7 out of 9 reported years for Progyny, using only its current SEC filer.

Year-to-year variability in free cash flow is volatile, measured at 39%.

These figures are automated calculations from SEC filings and the recent price. They are not a recommendation to buy or sell. See how we estimate value.

Dividends are not in our data for Progyny.

Compared With Its Sector and Industry

How to read this: the price to earnings ratio.

Its trailing P/E ratio is 60% above the average for stocks in the Healthcare sector.

Its trailing P/E ratio is in line with the average for stocks in the Medical Care Facilities industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

Closest Industry Peers

These are companies in the Medical Care Facilities industry, the ones closest in market capitalization to Progyny, limited to companies whose pages we publish. The figures come from our latest data for each company.

CompanyMarket cap (USD millions)P/EDividend yieldCash yieldPrice versus our estimate
Progyny (PGNY) 2,630 32.8 - - 409% above
Surgery Partners (SGRY) 3,505 - - - 105% above
Healthcare Services Group (HCSG) 1,667 16.7 - 4.0% 17% below
U.S. Physical Therapy (USPH) 1,432 - 1.9% 3.0% 1% below
DaVita (DVA) 10,129 12.2 - 15.2% 57% below
Universal Health Services (UHS) 10,345 7.5 0.5% 14.1% 71% below
Encompass Health Corporation (EHC) 13,114 21.4 0.6% - 438% above

Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.

Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 1551306.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • Free cash flow was negative in 2 of the 9 years we have.
  • Free cash flow is volatile from year to year, so the estimates depend heavily on which years are included.
  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2025
Price and market data last refreshed
2026-11-20
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: PGNY annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in PGNY

Does Progyny have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: PGNY

This example shows how we apply the Trendshare checklist to PGNY: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 35.71
    • Market cap: $2.6B
    • EPS: 1.09
  2. Step 2 — Valuation checks

    • P/E: 32.761
    • FCF yield: —
    • Date checked: Nov 20, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.